Iain James Macleod
Principal investigator.
Medtech
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2015First federal award
$13.2MFederal grants as PI15 awards
0Patents grantedNone matched
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
15 awards · $13.2M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Sep 2, 2026 | NIH | SBIR Phase II PANDAA for universal, pan-lineage molecular detection of filoviruses to enable rapid epidemic response. | $997K | ALDATU BIOSCIENCES INC |
| Jul 30, 2026 | NIH | SBIR Phase II PANDAA for universal, pan-lineage molecular detection of Crimean-Congo Hemorrhagic Fever virus. | $960K | ALDATU BIOSCIENCES INC |
| Aug 14, 2025 | NIH | SBIR Phase II PANDAA for universal, pan-lineage molecular detection of Crimean-Congo Hemorrhagic Fever virus. | $975K | ALDATU BIOSCIENCES INC |
| Jul 29, 2024 | NIH | SBIR Phase II PANDAA for universal, pan-lineage molecular detection of Crimean-Congo Hemorrhagic Fever virus. | $987K | ALDATU BIOSCIENCES INC |
| Jul 24, 2024 | NIH | SBIR Phase II PANDAA for universal, pan-lineage molecular detection of filoviruses to enable rapid epidemic response. | $943K | ALDATU BIOSCIENCES INC |
| Aug 4, 2023 | NIH | SBIR Phase II PANDAA for universal, pan-lineage molecular detection of filoviruses to enable rapid epidemic response. | $931K | ALDATU BIOSCIENCES INC |
| Jul 27, 2022 | NIH | SBIR Phase II PANDAA for universal, pan-lineage molecular detection of filoviruses to enable rapid epidemic response. | $964K | ALDATU BIOSCIENCES INC |
| Mar 2, 2022 | NIH | SBIR Phase II PANDAA for universal, pan-lineage molecular detection of Crimean-Congo Hemorrhagic Fever virus | $829K | ALDATU BIOSCIENCES INC |
| Mar 24, 2021 | NIH | SBIR Phase II PANDAA for universal, pan-lineage molecular detection of Crimean-Congo Hemorrhagic Fever virus | $866K | ALDATU BIOSCIENCES INC |
| Mar 27, 2019 | NIH | SBIR Phase I PANDAA for universal, pan-lineage molecular detection of Lassa fever infection | $300K | ALDATU BIOSCIENCES INC |
| Dec 21, 2018 | NIH | SBIR Phase II PANDAA for rapid genotyping of HIV-1 infected patients failing protease inhibitor ART in resource-limited settings | $967K | ALDATU BIOSCIENCES INC |
| Dec 13, 2017 | NIH | SBIR Phase II PANDAA for rapid genotyping of HIV-1 infected patients failing protease inhibitor ART in resource-limited settings | $974K | ALDATU BIOSCIENCES INC |
| Jan 16, 2017 | NIH | SBIR Phase II PANDAA for rapid genotyping of HIV-1 infected patients failing protease inhibitor ART in resource-limited settings | $998K | ALDATU BIOSCIENCES INC |
| Jun 3, 2016 | NIH | SBIR Phase II A Rapid, Cost-Effective HIV Drug Resistance Diagnostic for Resource-Limited Settings | $691K | ALDATU BIOSCIENCES INC |
| Mar 4, 2015 | NIH | SBIR Phase II A Rapid, Cost-Effective HIV Drug Resistance Diagnostic for Resource-Limited Settings | $773K | ALDATU BIOSCIENCES INC |
Peer ranks
Federal funding#34
Awards as PI#54
Patents#505
Companies
- ALDATU BIOSCIENCES INCLinked by awards · Medtech
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.